Category: biotech

.Merck &amp Co.’s TIGIT program has actually endured another misfortune. Months after shuttering a phase 3 melanoma ordeal, the Big Pharma has terminated a critical

.Merck &amp Co. has actually grabbed choices on pair of Evaxion Biotech injection prospects, paying out $3.2 million as well as hanging greater than $1

.Merck &amp Co.’s long-running initiative to land a punch on tiny cell lung cancer cells (SCLC) has racked up a little victory. The drugmaker’s Daiichi

.A phase 3 test of Daiichi Sankyo and also Merck &amp Co.’s HER3-directed antibody-drug conjugate (ADC) has actually attacked its main endpoint, enhancing strategies to

.Gilead Sciences and Merck &amp Co. have directed their once-weekly HIV combo treatment past one more milestone, connecting the mixed drink to sustained suppression of

.MBX has actually fleshed out plans to enjoy over $136 thousand coming from its IPO as the biotech aims to deliver a potential challenger to

.MBX Biosciences has added to the current flurry of IPO filings. The biotech, which filed its documentation full weeks after raising $63.5 million confidentially, is

.Following an inadequate showing for Lykos Therapeutics’ MDMA applicant for post-traumatic stress disorder at a latest FDA advising committee conference, the various other shoe has

.Psychopharmacology has actually drawn 3 write-ups concerning midstage scientific test information assessing Lykos Rehabs’ investigational MDMA candidate for treating post-traumatic stress disorder (PTSD). The publication

.Lykos Therapeutics might possess dropped three-quarters of its own team back the FDA’s being rejected of its own MDMA candidate for post-traumatic stress disorder, however